What Changed in the Amgen Story Amgen’s fair value estimate has been adjusted slightly, moving from about US$322.88 per share ...
The FDA is apparently not charmed by the mischievous “Lipid Lurkers” in an Esperion Therapeutics commercial for ...
However, if you're looking for a high-yield dividend stock in the Dow Jones, there are several to choose from today. Below ...
Zacks Investment Research on MSN
5 big drug stocks that may continue to outperform in 2026
After a weak first half, the drug and biotech sector has recovered in the past 2-3 months, with most large drugmakers signing drug pricing agreements with the Trump administration. After a cautious ...
SaveHealth reports on cholesterol medications, detailing common types like statins, their effects, and safety considerations ...
GoodRx , the leading platform for medication savings in the U.S., today announced the launch of RxSmartSaver powered by GoodRx at Giant Eagle pharmacies, giving patients a fast and easy way to access ...
Amgen Inc. raises 2025 revenue guidance on strong Repatha and Imdelltra sales and dividend hike. Click for this AMGN update.
Q. I developed severe depression while taking Repatha, the injectable cholesterol lowering drug. It took me a horrible nine months to realize the drug was making me suicidal. If I wasn’t sleeping, I ...
LIB Therapeutics has scored an FDA approval for its cholesterol-lowering, third-generation PCSK9 inhibitor, lerodalcibep-liga. The injected treatment, which will carry the commercial name Lerochol, is ...
LOWERING DRUG PRICES FOR AMERICAN PATIENTS: Today, President Donald J. Trump announced nine new agreements with major pharmaceutical companies to lower prescription drug prices for Americans in line ...
Using evolocumab (Repatha; Amgen) to treat stable patients with atherosclerotic cardiovascular disease (ASCVD) and obesity results in a larger decrease in major adverse cardiovascular events than it ...
Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback